Table 2.
Clinical Effectiveness of Abatacept in no-bionaïve and ABA-bionaïve patients.
| No-Bionaïve Patients | ||||
|---|---|---|---|---|
| Response Variable | 6 Months | 12 Months | ||
| N | % | N | % | |
| EULAR response | 120 | 105 | ||
| Satisfactory | 38 | 31.67 | 48 | 45.71 |
| Unsatisfactory | 82 | 68.33 | 57 | 54.29 |
| Remission (DAS28 < 2.6) | 18 | 15 | 29 | 27.62 |
| LDA (2.6 ≤ DAS28 ≤ 3.2) | 24 | 20 | 24 | 22.86 |
| ABA-bionaïve patients | ||||
| Response variable | 6 months | 12 months | ||
| EULAR response | 15 | 14 | ||
| Satisfactory | 8 | 53.33 | 11 | 78.57 |
| Unsatisfactory | 7 | 46.67 | 3 | 21.43 |
| Remission (DAS28 < 2.6) | 3 | 20 | 9 | 64.29 |
| LDA (2.6 ≤ DAS28 ≤ 3.2) | 5 | 33.33 | 3 | 21.43 |
DAS28: disease activity score in 28 joints; EULAR: European League Against Rheumatism criteria; LDA: low-activity disease; TNFi: tumor necrosis factor inhibitor.